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Introduction
Initial enthusiasm to explore gene expression proﬁ  ling 
and other high-throughput molecular methods as 
molecular diagnostic tools for breast cancer has given 
way to increasing skepticism. Several investigators 
suggested that these novel analytical methods may not 
have advanced diagnostic medicine beyond what 
optimally performed histology and immonohisto-
chemistry (IHC) could deliver. Th   ere is some truth in this 
criticism, particularly when it comes to clinically useful 
assays that gene expression proﬁ   ling methods have 
yielded. However, this overly simplistic assessment of 
molecular proﬁ   ling overlooks three important contri-
butions that high-throughput gene expression analysis 
has brought to breast cancer research and treatment. 
First, results from gene expression proﬁ  ling studies have 
fundamentally changed our conceptual approach to 
breast cancer. Second, these methods have yielded 
several commercially available new diagnostic tests that 
ﬁ  ll a previously unmet diagnostic niche and have started 
to impact routine care, at least in the United States. 
Th   ird, the impact of the large volume of molecular data 
that these studies have generated will have a lasting 
impact on breast cancer research. Th   e in-depth analysis 
of the many tantalizing observations made from compre-
hensive genomic characterization of breast cancers has 
barely begun.
The conceptual impact of molecular profi  ling on 
breast cancer research
Gene expression proﬁ  ling provided the ﬁ  rst glimpse of 
the true complexity of the molecular machinery of breast 
cancer. Th  e earliest of these studies already revealed 
large-scale molecular diﬀ   erences between estrogen 
receptor (ER)-positive and ER-negative cancers and also 
revealed two robust subsets within the ER-positive 
cancers [1]. Th   ese molecular diﬀ  erences between breast 
cancer subsets together with the important clinical 
diﬀ   erences that also distinguish these groups have 
prompted a conceptual shift in the classiﬁ  cation of breast 
cancer. Breast cancer is no longer considered a single 
disease with variable ER expression, histology and grade 
but a collection of genuinely diﬀ  erent neoplastic diseases 
that arise from the breast epithelium. Th  e  long 
recognized heterogeneity in ER expression and grade 
have not led to similar shifts in classiﬁ  cation in the past 
because the scale of molecular diﬀ   erences that exist 
between these disease types remained hidden until high-
throughput molecular analytical methods become avail-
able. Th  e implications of the new classiﬁ  cation schema 
reach far beyond a simple ER-based stratiﬁ  cation  of 
breast cancer. Diﬀ  erent molecular types of breast cancers 
will require separate clinical trials, diﬀ  erent prognostic 
and predictive markers and diﬀ  erent therapeutic strate-
gies. Continued conduct of studies that include all types 
of breast cancers is akin to conducting a trial for leukemia 
where patients with acute myeloid leukemia, acute 
lymphocytic leukemia, chronic lymphocytic leukemia, 
chronic myeloid leukemia, and so on, are all eligible for 
participation. Results from such studies would be 
unstable and have limited practical value considering the 
vast clinical and molecular diﬀ   erences between these 
diﬀ  erent types of leukemias. Indeed, the next generation 
of thera  peutic and biomarker studies in breast cancer are 
increasingly being targeted to molecularly deﬁ  ned 
subsets such as triple-negative/basal-like or ER-positive 
high risk (Luminal A or MammaPrint or Oncotype Dx 
high risk groups) breast cancers.
The impact of molecular profi  ling on molecular 
diagnostics
Molecular proﬁ   ling simultaneously measures a large 
number of variables (that is, gene expression values, 
DNA copy numbers or single nucleotide polymorphisms) 
and the simplest goal of the analysis is to ﬁ  nd individual 
variables that are associated with a disease subset or  © 2010 BioMed Central Ltd
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into focus two very important statistical concepts, long 
neglected in traditional biomarker research: the impor-
tance of combining individual, independent markers into 
multivariate prediction models; and the need to guard 
against false discovery due to multiple comparisons. 
Invariably, more than one marker is associated with any 
particular out  come or disease subset. Historically, 
markers were used as stratiﬁ  cation tools and classiﬁ  cation 
schemas were either restricted to a single marker (that is, 
groups were deﬁ  ned as marker high versus marker low) 
or multiple markers were used as sequential stratiﬁ  cation 
tools. However, subsetting of patients through multiple 
layers of dichotomous markers is not practical and leads 
to unstable results due to the rapidly diminishing 
numbers in the subsets. Th  e statistically optimal use of 
indepen  dent variables is to construct a multivariate 
prediction model. Despite close to four decades of IHC 
literature, very few papers describe correctly trained and 
indepen  dently validated multivariate prediction models. 
Th  is has started to change lately, due to the impact of 
molecular proﬁ   ling studies, and will undoubtedly 
increase the value of IHC-based tests through combining 
multiple diﬀ   erent IHC markers into more powerful 
prediction models.
Molecular proﬁ  ling also brought into the forefront the 
importance of guarding against false positive discoveries 
due to multiple comparisons. When only a single marker 
is assessed and a 5% signiﬁ  cance level is applied to the 
statistical test, there is only a 5% chance of incorrectly 
rejecting the null hypothesis (that is, lack of association 
between a marker and an outcome) if the null hypothesis 
is correct. However, if one performs 100 independent 
tests where all null hypotheses are correct, the expected 
number of false positive ﬁ  ndings is 5. Th   e probability of 
ﬁ  nding at least one positive association among the 100 
tests is virtually 100% even if none of the markers is 
associated with the endpoint. Historically, IHC studies 
often evaluated multiple diﬀ  erent markers and the same 
marker may have been correlated with several diﬀ  erent 
endpoints, yet adjustments for the multiple hypothesis 
testing were rarely performed. More recently, investiga-
tors and journal editors started to require such adjust-
ments even in ‘low throughput’ multiple compari  son 
studies, which will raise the level of evidence that these 
analyses produce.
Perhaps the most important practical contribution of 
genomics to breast cancer management was the develop-
ment of multi-gene assays (Oncotype Dx, MammaPrint, 
Genomic Grade Index) that can distinguish low and high 
risk prognostic groups among ER-positive, early stage 
breast cancers [2,3]. In the past, selection of adjuvant 
chemotherapy for ER-positive cancers was based on 
tumor size, nodal status, histologic grade, patient 
preference, and comorbid illnesses. However, none of 
these variables, with the exception of grade, has a 
consistent association with sensitivity to chemotherapy 
or endocrine therapy. Combination of these variables 
into a summary recommendation about therapy is 
subjective and frequently leads to variable recommen-
dations by diﬀ   erent physicians. Multivariate genomic 
assays that take input from ER and human epidermal 
growth factor receptor 2 (HER2) expression as well as 
from a number of proliferation-related genes can stratify 
ER-positive cancers into low and high risk prognostic 
groups objectively and this information is additive or 
complementary to prognostic risk based on tumor size 
and nodal status. Th  ese assay results can also inform 
about general chemotherapy sensitivity [4,5]. It has also 
become apparent that the most important prognostic 
and predictive component of these ﬁ  rst generation assays 
comes from their ability to measure proliferation 
reproducibly and quantitatively [6]. Hence, simpler 
proliferation measurements may accomplish the same. 
However, an important feature of these commercially 
available tests is that they are standardized and validated 
in multiple independent studies. Multi-IHC tests, 
including ER, progesterone receptor, HER2, Ki67 (and 
other genes) may accomplish similar risk stratiﬁ  cation in 
the future but, currently, despite over 25 years of 
research, no standardized and externally validated IHC-
based risk stratiﬁ  cation assay exists for breast cancer.
Future potential
Molecular proﬁ  ling is uniquely suited for multiplex assays. 
A single assay from one needle biopsy specimen can 
generate a large number of data points. A variable 
assortment of diﬀ  erent genes (or other molecular variable) 
can be used to issue simultaneously several diﬀ  erent 
prognostic or predictive results. Th  e cost of gene 
expression analysis has dropped substantially over the 
past few years and the analytical validity of the diﬀ  erent 
platforms is well established [7,8]. Gene expression 
results and other molecular readouts are quantitative 
over a relatively broad dynamic range and can easily be 
fed into standardized computer prediction algorithms. 
On the other hand, multiplex IHC assays are 
cumbersome to perform and the quantiﬁ  cation of the 
signal is still not standardized across pathology labora-
tories. It is hard to imagine that one could perform more 
than a few multi-IHC tests on the same case if each tests 
relies on measuring four to six diﬀ  erent antigenes that 
require individual sections and separate scoring. 
Combin  ing the individual IHC results into several 
diﬀ   erent multi-IHC scores is not well suited for 
automation and could be error prone if performed by 
humans. Th   e future of molecular proﬁ  ling as a diagnostic 
tool will depend to a large extent on the content that can 
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useful, validated predictive signatures can be developed, 
molecular proﬁ   ling has a bright future as diagnostic 
technology. Th  e more such signatures exist, the greater 
the utility of a high-throughput, standardized, easily 
automated platform.
Finally, the impact of the large volumes of public data 
that molecular proﬁ  ling studies have generated cannot be 
compared with the impact of IHC studies that measure 
the expression of one or a handful of genes [9]. Th  e  in-
depth analysis of the many tantalizing observations made 
from comprehensive genomic characterization of breast 
cancers has barely begun and may ultimately represent 
the most important future contribution of molecular 
proﬁ  ling to cancer research.
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